PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV. Subcutaneous lenacapavir is administered twice a year (every six months) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at risk. With patients only needing lenacapavir twice a year for HIV prevention, the field has been optimistic about the potential for lenacapavir to reduce barriers and improve access to PrEP. Since we are still early in the rollout subcutaneous lenacapavir, many providers have questions about how to offer it to their patients—from workflow to billing to managing potential side effects and drug-drug interactions.

On this episode, Antonio Urbina, MD, Medical Director for CEI’s HIV Primary Care and Prevention Center of Excellence, speaks with Alex Danforth, PharmD. Alex Danforth is a clinical pharmacist in Rochester, NY. She practices at Trillium Health, a federally qualified health center, where she works with patients and providers to help manage medications and optimize care. Alex currently provides clinical leadership for HIV treatment and prevention programs.

Drs. Urbina and Danforth talk about the latest New York State Clinical Guidelines for PrEP, which were updated on October 16th. The new guidelines provide important updates, including subcutaneous lenacapavir. They discuss important considerations for initiating patients on lenacapavir as well as some early lessons learned from implementing lenacapavir in their Rochester- and New York City-based clinics. Related Content:

Jaksot(60)

Special Conversations with CEI: The Impact of Hepatitis C Screening during Pregnancy: A Client’s Story

Special Conversations with CEI: The Impact of Hepatitis C Screening during Pregnancy: A Client’s Story

Hepatitis C virus (HCV) is a pathogen spread by contact with blood from a person with HCV infection. Prevalence among the US obstetric population rose nearly 10-fold over the past 20 years and approxi...

30 Touko 202436min

Would you consider Injectable ART for those unable to suppress with oral HIV treatment?

Would you consider Injectable ART for those unable to suppress with oral HIV treatment?

In this episode, Dr. Steven Fine discusses some of the latest data that might be used to support starting patients who are unable to take oral antiretroviral medications on long acting, injectable ARV...

7 Touko 202414min

HIV Prevention Research in the Kink-Involved Population

HIV Prevention Research in the Kink-Involved Population

Cultural humility in healthcare, especially for those involved in kink, requires going beyond basic competence. Clinicians must provide respectful care, acknowledging patients' diverse backgrounds and...

11 Huhti 202423min

Doxy-PEP Part II: Where Are We Now?

Doxy-PEP Part II: Where Are We Now?

In this episode, Dr. Marguerite Urban and Dr. Daniela DiMarco pick up from the November 2023 episode of Conversations with CEI, where they talked about Doxy-PEP for the prevention of sexually transmit...

14 Maalis 202417min

Tackling Stigma with Compassion: Harm Reduction in Clinical Practice

Tackling Stigma with Compassion: Harm Reduction in Clinical Practice

Harm reduction is a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use. It is also a movement for social justice build on a belief in, and respect f...

8 Helmi 202428min

RSV Vaccination in HIV Positive Adults

RSV Vaccination in HIV Positive Adults

RSV vaccine for adults has recently become available and can protect against severe disease or death from one of the main causes of upper respiratory infections. HIV patients are asking if they should...

11 Tammi 202411min

We can do it! Improving access to care for transgender and gender diverse patients

We can do it! Improving access to care for transgender and gender diverse patients

Compared with the general population, transgender and gender diverse people are more likely to experience poor health outcomes, such as chronic health conditions, HIV, substance use, and mental illnes...

14 Joulu 202317min

What is Doxy-PEP?  A Conversation about the Use of Doxycycline Post Exposure Prophylaxis to Prevent STIs

What is Doxy-PEP? A Conversation about the Use of Doxycycline Post Exposure Prophylaxis to Prevent STIs

In this episode, Dr. Marguerite Urban and Dr. Daniela DiMarco discuss Doxy-PEP, a new tool for the prevention of bacterial STIs.  Drs. Urban and DiMarco are infectious disease faculty members at the U...

9 Marras 202315min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
voi-hyvin-meditaatiot-2
rss-narsisti
adhd-podi
psykopodiaa-podcast
rss-rahamania
rss-uskonto-on-tylsaa
rss-valo-minussa-2
rss-vapaudu-voimaasi
rss-duodecim-lehti
rss-niinku-asia-on
mielipaivakirja
rahapuhetta
aamukahvilla
ilona-rauhala
kesken
dear-ladies
rss-eron-alkemiaa
nakokulmia-rikollisuudesta-irrottautumiseen
rss-arkea-ja-aurinkoa-podcast-espanjasta